Taylor H. Schreiber, Ph.D.
Affiliations: | 2010 | University of Miami, Coral Gables, FL |
Area:
Oncology, ImmunologyGoogle:
"Taylor Schreiber"Parents
Sign in to add mentor| Eckhard R. Podack | grad student | 2010 | University of Miami | |
| (Balancing effector and regulatory T cell responses in cancer and autoimmunity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang C, Lai AY, Baiu DC, et al. (2023) Analysis of Butyrophilin-Mediated Activation of γδ T Cells from Human Spleen. Journal of Immunology (Baltimore, Md. : 1950) |
| Shuptrine CW, Perez VM, Selitsky SR, et al. (2023) Shining a LIGHT on myeloid cell targeted immunotherapy. European Journal of Cancer (Oxford, England : 1990). 187: 147-160 |
| Lai AY, Patel A, Brewer F, et al. (2022) Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2 T Cells in the Presence of Costimulation by CD28 or NKG2D. Journal of Immunology (Baltimore, Md. : 1950) |
| Yoo KJ, Johannes K, González LE, et al. (2022) LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade. Journal of Immunology (Baltimore, Md. : 1950) |
| de Silva S, Fromm G, Shuptrine CW, et al. (2019) CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. Cancer Immunology Research |
| Schreiber TH, Fromm G, Silva SD, et al. (2019) Abstract 2271: Development and characterization of SL-115154 (CSF1R-Fc-CD40L) for cancer immunotherapy Cancer Research. 79: 2271-2271 |
| Fromm G, de Silva S, Johannes K, et al. (2018) Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. Journal For Immunotherapy of Cancer. 6: 149 |
| Triplett TA, Garrison KC, Marshall N, et al. (2018) Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nature Biotechnology |
| Fromm G, Silva Sd, Johannes K, et al. (2018) Abstract 5567: Agonist redirected checkpoint (ARC), SIRPα-Fc-CD40L, for cancer immunotherapy Cancer Research. 78: 5567-5567 |
| Fromm G, Silva Sd, Johannes K, et al. (2018) Abstract 5564: Agonist redirected checkpoint, VSIG8-Fc-OX40L, for cancer immunotherapy Cancer Research. 78: 5564-5564 |